Pazopanib in Patients With Relapsed or Refractory Small Cell Lung Cancer
Status:
Completed
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
Pazopanib is a drug that inhibits proteins thought to be important for new blood vessel
formation. This drug has been used in other cancer research studies and information from
those studies suggests that pazopanib may help block proteins that are important for the
growth, invasion, and spread of cancer cells.
Phase:
Phase 2
Details
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborators:
Beth Israel Deaconess Medical Center Brigham and Women's Hospital GlaxoSmithKline Massachusetts General Hospital